:internalReference - lisinopril-dihydrate | 83915-83-7
Es wurde leider kein Produkt mit der Referenz :internalReference gefunden, aber bitte schauen Sie sich die folgenden ähnlichen Produkte an:
Lisinopril Dihydrate
CAS:Formel:C21H31O5N3·2H2OReinheit:>98.0%(T)Farbe und Form:White to Almost white powder to crystalMolekulargewicht:441.53Lisinopril dihydrate
CAS:Lisinopril dihydrateFormel:C21H31N3O5Reinheit:91.5%Farbe und Form:WhiteMolekulargewicht:405.22637Lisinopril dihydrate
CAS:Lisinopril dihydrate （MK-521) is an orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity.Formel:C21H35N3O7Reinheit:98.83% - 99.22%Farbe und Form:White To Off-White Crystalline PowderMolekulargewicht:441.52Lisinopril dihydrate
CAS:Kontrolliertes ProduktFormel:C21H31N3O5H2OFarbe und Form:NeatMolekulargewicht:441.52Lisinopril Dihydrate
CAS:Kontrolliertes ProduktFormel:C21H31N3O5H2OFarbe und Form:NeatMolekulargewicht:441.52LISINOPRIL DIHYDRATE CRS
CAS:LISINOPRIL DIHYDRATE CRSFormel:C21H35N3O7Farbe und Form:PowderMolekulargewicht:441.5185Lisinopril dihydrate, 10mM (in H2O)
CAS:Lisinopril dihydrate, 10mM (in H2O)Reinheit:≥98%Molekulargewicht:441.52g/mol(S)-Lisinopril Dihydrate
CAS:Stability Hygroscopic
Applications An orally active angiotensin-converting enzyme (ACE) inhibitor. S,S,S-Isomer of Lisinopril.
References Goa, K.L., et al.: Drugs, 52, 564 (1996), Chaturvedi, N., et al.: Lancet, 351, 28 (1998)Formel:C21H31N3O5·2H2OFarbe und Form:WhiteMolekulargewicht:441.52LISINOPRIL FOR SYSTEM SUITABILITY A CRS
CAS:LISINOPRIL FOR SYSTEM SUITABILITY A CRSFarbe und Form:PowderLisinopril
CAS:Cardiovascular drugs, not elsewhere specified or includFormel:C21H31N3O5·2H2OFarbe und Form:White Off-White PowderMolekulargewicht:405.226372-Deoxy-3,4,6-tri-O-pivaloyl-D-glucopyranosyl azide
CAS:2-Deoxy-3,4,6-tri-O-pivaloyl-D-glucopyranosyl azide is a drug that regulates the blood pressure. It is an oral hypoglycaemic agent that has been shown to lower blood sugar levels in patients with type 2 diabetes mellitus. The drug is metabolized in the liver by cytochrome p450 enzymes and can cause interactions with drugs such as lisinopril, which are metabolized by these enzymes. 2DGPA has been shown to be effective at lowering blood pressure in a low-dose group of patients with essential hypertension. The signal peptide sequence was detected in the protein sequencing of a biological sample from rats treated with 2DGPA. This drug also reduces natriuretic peptide levels and has a rate constant of 4s−1M−1s−1.Formel:C21H35N3O7Reinheit:Min. 95%Molekulargewicht:441.53 g/molL-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)
CAS:Formel:C21H35N3O7Reinheit:99%Farbe und Form:SolidMolekulargewicht:441.5185Lisinopril
CAS:Formel:C21H31O5N3·2H2OReinheit:(Titration) 98.0 - 102.0 % (anhydrous basis)Farbe und Form:White to almost white crystalline powderMolekulargewicht:441.52
![L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb-webp%2FDA003RAL.webp&w=3840&q=75)
